, /PRNewswire/ -- , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of , Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding , Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering.
In addition, Alltrna also announced the appointments to the company's Board of Directors of , founding Chief Operating Officer of Ionis Pharmaceuticals, , M.D., Ph.
D., Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, and , M.D.
, Founding CEO of Syros Pharmaceuticals. They join Board Directors , Alltrna CEO and Flagship Pioneering CEO-Partner, and , Ph.D.
, MBA, Alltrna Co-Founder and Flagship Pioneering General Partner. "As a Co-Founder of Alltrna and Board Chairperson since 2018, I've been honored to guide Alltrna from ideation to platform creation to preclinical proof-of-concept," said , Ph.D.
, Founder and CEO of Flagship Pioneering and Co-Founder of Alltrna. "As Alltrna looks to bring its first tRNA medicines into the clinic, Chris' expertise in company development, partnering, and financing will be indispensable. With Chris leading the Board and the additions of Lynne, Robert, and Nancy, Alltrna is exceptionally well-positioned to fulfill this enormous opportunity leveraging the unique biology of tRNA to scale the development of genetic medicines for many diseases.
" "N.